Labcorp Holdings Inc. (LH)
| Market Cap | 22.28B |
| Revenue (ttm) | 13.77B +8.3% |
| Net Income | 855.20M +96.4% |
| EPS | 10.19 +98.4% |
| Shares Out | 82.90M |
| PE Ratio | 26.31 |
| Forward PE | 15.63 |
| Dividend | $2.88 (1.07%) |
| Ex-Dividend Date | Feb 27, 2026 |
| Volume | 300,267 |
| Open | 267.82 |
| Previous Close | 268.04 |
| Day's Range | 266.58 - 269.98 |
| 52-Week Range | 209.38 - 293.72 |
| Beta | 0.97 |
| Analysts | Strong Buy |
| Price Target | 301.33 (+12.12%) |
| Earnings Date | Feb 17, 2026 |
About LH
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target... [Read more]
Financial Performance
In 2024, Labcorp Holdings's revenue was $13.01 billion, an increase of 6.97% compared to the previous year's $12.16 billion. Earnings were $746.00 million, an increase of 78.47%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for LH stock is "Strong Buy." The 12-month stock price target is $301.33, which is an increase of 12.12% from the latest price.
News
Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026
BURLINGTON, N.C., Jan. 15, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth...
Labcorp Declares Quarterly Dividend
BURLINGTON, N.C., Jan. 14, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has d...
Labcorp Holdings Inc. (LH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Labcorp Holdings Inc. (LH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk
Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imaging Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA non-sm...
Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs
SAN JOSE, Calif.--(BUSINESS WIRE)--Today, Visby Medical announced two new relationships that will expand national access to the Visby Women's Sexual Health Test, the first, at-home, FDA-authorized PCR...
NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp
TOLEDO, Ohio, Jan. 8, 2026 /PRNewswire/ -- NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of th...
Labcorp to Speak at the 44th Annual J.P. Morgan Healthcare Conference
BURLINGTON, N.C., Dec. 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a fireside...
Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care Networks
ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Lab...
Community Health Systems Completes Sale of Select Outreach Laboratory Assets to Labcorp
FRANKLIN, Tenn. & BURLINGTON, N.C.--(BUSINESS WIRE)--Community Health Systems, Inc. (the “Company”) (NYSE: CYH) announced today that its subsidiary, CHS/Community Health Systems, Inc. (CHS), has compl...
Labcorp Appoints Victor Bulto to Board of Directors
Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: L...
Labcorp® Plasma Detect™ Clinical Studies Featured in Nature Medicine and Clinical Cancer Research
Studies demonstrate Labcorp Plasma Detect MRD Technology can inform treatment strategies and advance cancer research BURLINGTON, N.C. , Nov. 19, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leade...
Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research
DURHAM, N.C. and SEOUL, South Korea , Nov. 17, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and compre...
Labcorp Positioned For Gradual Upside With Resilient Margins And Dividend Support
Laboratory Corp (NYSE: LH) reported third-quarter 2025 adjusted earnings per share of $4.18 on Tuesday, up from $3.50 a year ago, beating the consensus of $4.18.
Labcorp Holdings Inc. (LH) Q3 2025 Earnings Call Transcript
Labcorp Holdings Inc. (NYSE:LH) Q3 2025 Earnings Call October 28, 2025 9:00 AM EDT Company Participants Christin O'Donnell - Vice President of Investor Relations Adam Schechter - President, CEO & Cha...
Labcorp lifts annual profit forecast on strong diagnostic test demand
Labcorp on Tuesday raised its annual profit forecast and beat estimates in the third quarter as the laboratory operator benefited from strong demand for its diagnostic tests.
Labcorp Announces 2025 Third Quarter Results
Updates Full-Year Guidance Financial results from Operations for third quarter 2025 versus third quarter 2024: Revenue: $3.56 billion versus $3.28 billion Diluted EPS: $3.12 versus $2.00 Adjusted EPS:...
Labcorp to Offer First FDA-Cleared Blood Test to Rule out Alzheimer's-Related Amyloid Pathology in Primary Care Settings
Labcorp plans to make Roche's Elecsys® pTau181 test available nationwide by early 2026 BURLINGTON, N.C. , Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehens...
Praia Health, Providence, and Labcorp Collaborate to Transform Patient Engagement and Lab Order Adherence
CHICAGO--(BUSINESS WIRE)--A streamlined digital experience improved lab order adherence, reduced no-shows, and enhanced operational efficiency at Providence.
Labcorp Announces Collaboration with Roche to Advance Digital Pathology Capabilities
Labcorp to leverage Roche's digital pathology technology to expand access, enhance efficiency and support AI integration across anatomic pathology services BURLINGTON, N.C. , Sept. 30, 2025 /PRNewswir...
Labcorp to Announce Third Quarter Financial Results on October 28, 2025
BURLINGTON, N.C. , Sept. 25, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the thir...
Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
BURLINGTON, N.C. and MIAMI , Sept.
Labcorp Holdings Inc. (LH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Labcorp Holdings Inc. (NYSE:LH) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Adam Schechter - President, CEO & Chairman Julia Wang - CFO ...
Labcorp to Speak at the Morgan Stanley 23rd Annual Global Healthcare Conference
BURLINGTON, N.C. , Aug. 27, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team ...
Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease
Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C. , Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...
Labcorp Introduces Test Finder, a First-of-Its-Kind Generative AI Tool to Simplify Lab Test Search
Test Finder interprets provider questions in context to deliver curated, clinically relevant results, going beyond traditional search Developed in collaboration with Amazon Web Services, Test Finder i...